Hepatotoxicity of metronidazole in Cockayne syndrome: A clinical report

Eur J Med Genet. 2022 Jan;65(1):104388. doi: 10.1016/j.ejmg.2021.104388. Epub 2021 Nov 9.

Abstract

Cockayne syndrome (CS) is a rare autosomal recessive genetic disorder characterized by growth failure and progressive multisystem dysfunction caused by deficient nucleotide excision repair. Whereas metronidazole (MTZ) hepatotoxicity is quite rare in the general population, cases of severe hepatic reaction to MTZ have been reported in CS patients. We report here the case of a 21-year-old CS patient who presented with jaundice following one week of treatment with MTZ combined with spiramycin for dental care. This case is the first one documented with a liver biopsy. Histopathological analysis revealed portal and lobular inflammation with predominance of neutrophils, ballooning degeneration and severe cholestasis without bile duct damage. The outcome was marked by regression of jaundice over 6 weeks. Analysis of this case highlights the probable responsibility of MTZ and adds support to the recommendation to strictly avoid the prescription of this drug in CS patients.

Keywords: Cockayne syndrome; Hepatotoxicity; Metronidazole; Spiramycin.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anti-Infective Agents / adverse effects*
  • Chemical and Drug Induced Liver Injury* / pathology
  • Cockayne Syndrome* / pathology
  • Humans
  • Jaundice / chemically induced
  • Jaundice / pathology
  • Liver / drug effects
  • Liver / pathology
  • Male
  • Metronidazole / adverse effects*
  • Young Adult

Substances

  • Anti-Infective Agents
  • Metronidazole